Dupixent (dupilumab)

He had tried superpotent topical corticosteroids and oral prednisolone, as well as emollients, none of which had improved his symptoms...Tralokinumab was trialled for 12 weeks, as this has a single therapeutic target (interleukin-13), but unfortunately there was no improvement. Following discussion with the immunologists, he was commenced on upadacitinib as this was felt to have a more targeted immunosuppressive effect above agents such as methotrexate and dupilumab. We await his next follow-up appointment to assess response. This case highlights the complexity of treating an immunocompromised individual with immunosuppressive agents, when the cause of their immunosuppression is unknown.

The patient was started on immunoglobulin infusions and dupilumab, with some improvement in his eczematous rash, before receiving a 100% matched unrelated-donor haematopoietic stem cell transplantation (HSCT)...However, the molecular link between DOCK8 deficiency and atopic skin inflammation remains unknown. This case highlights the importance of considering inborn errors of immunity in such cases of severe eczema associated with apparent immune dysregulation and susceptibility to recurrent infections.

P=N/A, N=40, Recruiting, UMC Utrecht

P4, N=30, Enrolling by invitation, University of North Carolina, Chapel Hill | Recruiting --> Enrolling by invitation | Trial completion date: Aug 2026 --> Dec 2026

P=N/A, N=112, Completed, Sanofi | Active, not recruiting --> Completed

Dupilumab is a safe and highly effective therapeutic option for pediatric patients with IEI-associated atopic manifestations, improving clinical outcomes, quality of life, and infection profile while preserving immune function. These findings support broader application of dupilumab in patients with IEI and warrant further investigation in larger, multicenter studies.

P2, N=66, Recruiting, National University Hospital, Singapore | Not yet recruiting --> Recruiting | Initiation date: Aug 2025 --> Nov 2025

P=N/A, N=350, Recruiting, Sanofi | Not yet recruiting --> Recruiting

P=N/A, N=20, Recruiting, Children's Hospital of Fudan University

P4, N=0, Withdrawn, Regeneron Pharmaceuticals | N=85 --> 0 | Not yet recruiting --> Withdrawn

P1/2, N=33, Completed, Thomas Marron | Recruiting --> Completed | N=21 --> 33 | Trial completion date: Dec 2026 --> Nov 2025

Importantly, some skin toxicities may correlate with favorable anti-tumor responses. This article comprehensively reviews epidemiology, pathophysiology, clinical presentations, including rare and emerging patterns, diagnostic strategies, management protocols, and future directions in the understanding and treatment of cutaneous irAEs induced by immunotherapy.